

Michael J Birrer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/700580/publications.pdf>

Version: 2024-02-01

111
papers

7,269
citations

94269

37
h-index

58464

82
g-index

138
all docs

138
docs citations

138
times ranked

12557
citing authors

#	ARTICLE	IF	CITATIONS
1	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
2	Inherited Mutations in Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 482.	3.4	576
3	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1207-1214.	5.1	523
4	Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). <i>Lancet</i> , The, 2017, 390, 1654-1663.	6.3	424
5	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
6	ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. <i>Genes and Development</i> , 2017, 31, 318-332.	2.7	307
7	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 738-748.	13.9	303
8	Antibody-Drug Conjugate-Based Therapeutics: State of the Science. <i>Journal of the National Cancer Institute</i> , 2019, 111, 538-549.	3.0	257
9	Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13948-13953.	3.3	221
10	CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 5522-5534.	0.4	206
11	Olaparib and \pm -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	5.1	191
12	Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	184
13	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1112-1118.	0.8	158
14	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. <i>Nature Communications</i> , 2014, 5, 5092.	5.8	112
15	Comparative Meta-analysis of Prognostic Gene Signatures for Late-Stage Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	110
16	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 589-606.	3.9	105
17	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. <i>Gynecologic Oncology</i> , 2015, 136, 246-253.	0.6	104
18	Early tumor detection afforded by in vivo imaging of near-infrared II fluorescence. <i>Biomaterials</i> , 2017, 134, 202-215.	5.7	100

#	ARTICLE	IF	CITATIONS
19	A functional variant in <i>HOXA11-AS</i> , a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. <i>Oncotarget</i> , 2015, 6, 34745-34757.	0.8	98
20	Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α -targeting antibody-drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.	2.0	94
21	Somatic Mosaic Mutations in <i>PPM1D</i> and <i>TP53</i> in the Blood of Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 370.	3.4	88
22	Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. <i>Journal of the American Chemical Society</i> , 2017, 139, 3033-3044.	6.6	74
23	Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	74
24	Characterization of folate receptor alpha (FR α) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR α -targeting antibody-drug conjugate mirvetuximab soravtansine. <i>Gynecologic Oncology</i> , 2017, 147, 402-407.	0.6	73
25	Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. <i>Nature Communications</i> , 2017, 8, 2166.	5.8	71
26	Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 808-818.	3.2	70
27	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 62-69.	0.6	70
28	Real-Time Single-Walled Carbon Nanotube-Based Fluorescence Imaging Improves Survival after Debulking Surgery in an Ovarian Cancer Model. <i>ACS Nano</i> , 2019, 13, 5356-5365.	7.3	70
29	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. <i>Clinical Cancer Research</i> , 2015, 21, 4960-4969.	3.2	62
30	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249.	0.6	61
31	A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 123-136.	1.1	60
32	Targeting the Nuclear Import Receptor Kpn1 ²¹ as an Anticancer Therapeutic. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 560-573.	1.9	57
33	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 1669-1678.	1.1	55
34	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 46-52.	0.6	48
35	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. <i>Anticancer Research</i> , 2014, 34, 811-817.	0.5	46
36	AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4418-27.	3.3	45

#	ARTICLE	IF	CITATIONS
37	Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6417-6428.	3.2	39
38	Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. <i>Clinical Cancer Research</i> , 2019, 25, 1727-1736.	3.2	39
39	CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. <i>PLoS ONE</i> , 2016, 11, e0156595.	1.1	38
40	Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. <i>Cell Reports</i> , 2019, 27, 255-268.e6.	2.9	38
41	Biomarkers in ovarian cancer: To be or not to be. <i>Cancer</i> , 2019, 125, 4563-4572.	2.0	38
42	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 2749-2757.	3.2	37
43	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.	0.8	37
44	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940.	3.2	35
45	Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities. <i>Gynecologic Oncology</i> , 2016, 142, 248-254.	0.6	34
46	The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 509-519.	1.1	34
47	Phase II, stage, arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. <i>International Journal of Cancer</i> , 2020, 147, 413-422.	2.3	31
48	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. <i>Clinical Cancer Research</i> , 2020, 26, 1288-1296.	3.2	29
49	ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. <i>Cancers</i> , 2018, 10, 464.	1.7	28
50	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2017, 146, 247-253.	0.6	23
51	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. <i>Journal of Pathology</i> , 2018, 246, 459-469.	2.1	23
52	Overexpression of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2020, 156, 423-429.	0.6	23
53	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 374-381.	1.2	22
54	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). <i>Journal of Clinical Oncology</i> , 2013, 31, 5524-5524.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016, 141, 43-48.	0.6	21
56	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 648-653.	0.6	21
57	Inhibition of the Wnt/ β -catenin pathway enhances antitumor immunity in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091379.	1.4	21
58	Molecular Subtypes of High-Grade Serous Ovarian Cancer: The Holy Grail?. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	18
59	The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw146.	3.0	18
60	Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin+paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5505-5505.	0.8	18
61	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 118-122.	0.3	17
62	Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. <i>Cancer Cell</i> , 2015, 28, 7-9.	7.7	15
63	Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. <i>Journal of Controlled Release</i> , 2015, 220, 358-367.	4.8	15
64	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology+Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2363-2370.	1.9	15
65	Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. <i>Oncotarget</i> , 2017, 8, 96482-96495.	0.8	15
66	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 177-178.	2.0	14
67	Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv442.	3.0	13
68	Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. <i>Oncologist</i> , 2018, 23, 697-703.	1.9	12
69	Phase 1 study of IMGN853, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5558-5558.	0.8	12
70	A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2573-2573.	0.8	11
71	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA5500-LBA5500.	0.8	11
72	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2016, 11, 317-327.	1.7	10

#	ARTICLE	IF	CITATIONS
73	Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5535-5535.	0.8	9
74	A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA5500-LBA5500.	0.8	8
75	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	0.6	7
76	Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. <i>American Journal of Clinical Pathology</i> , 2020, 153, 149-155.	0.4	7
77	Preliminary single agent activity of IMGN853, a folate receptor alpha (FR β)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5518-5518.	0.8	7
78	A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5555-5555.	0.8	7
79	Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR β)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5547-5547.	0.8	7
80	Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 396-401.	0.6	6
81	A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5571-5571.	0.8	6
82	Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and <i>POLE</i> -mutated recurrent or persistent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5615-TPS5615.	0.8	6
83	Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5516-5516.	0.8	5
84	Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin+paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5521-5521.	0.8	5
85	Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FR β)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5553-5553.	0.8	5
86	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2017, 146, 137-145.	0.6	4
87	Ovarian cancer: individualized and personalized care. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 409-419.	0.4	3
88	Ovarian Cancer: Targeting the Untargetable. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 13-15.	1.8	3
89	Variation in resource utilization associated with the surgical management of ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 587-593.	0.6	3
90	IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FR β)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5567-5567.	0.8	3

#	ARTICLE	IF	CITATIONS
91	A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).. Journal of Clinical Oncology, 2016, 34, 5569-5569.	0.8	3
92	FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FR α)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.. Journal of Clinical Oncology, 2017, 35, TPS5607-TPS5607.	0.8	3
93	Risk stratification after recurrence of human papillomavirus (HPV) α -related and non α -HPV α -related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. Head and Neck, 2021, 44, 158.	0.9	3
94	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum α -sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer, 2016, 122, 3297-3306.	2.0	2
95	OPSALIN: A phase II placebo-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer treated with carboplatin (Cb) and paclitaxel (P).. Journal of Clinical Oncology, 2012, 30, TPS5112-TPS5112.	0.8	2
96	A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.. Journal of Clinical Oncology, 2015, 33, 5559-5559.	0.8	2
97	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 5592-5592.	0.8	2
98	A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.. Journal of Clinical Oncology, 2012, 30, 5029-5029.	0.8	1
99	An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience.. Journal of Clinical Oncology, 2013, 31, 5534-5534.	0.8	1
100	Real-time single-walled nanotube (SWNT)-based imaging system to improve tumor detection and survival in ovarian cancer preclinical model.. Journal of Clinical Oncology, 2016, 34, 5530-5530.	0.8	1
101	Targeting VEGFRi resistance through HIF-1 α suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer.. Journal of Clinical Oncology, 2015, 33, TPS5614-TPS5614.	0.8	1
102	Ovarian Cancer Maintenance: Practice α -Changing Data Calls for Changing Practice. Oncologist, 2019, 24, 576-579.	1.9	0
103	Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO.. Journal of Clinical Oncology, 2013, 31, 6579-6579.	0.8	0
104	A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant M α llerian cancer.. Journal of Clinical Oncology, 2015, 33, 5542-5542.	0.8	0
105	The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study.. Journal of Clinical Oncology, 2015, 33, e16509-e16509.	0.8	0
106	Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5551-5551.	0.8	0
107	Quality of life among long-term ovarian cancer survivors.. Journal of Clinical Oncology, 2016, 34, e21570-e21570.	0.8	0
108	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC).. Journal of Clinical Oncology, 2017, 35, 241-241.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	0
110	Harnessing IMGN853-mediated cell cytotoxicity response by modulating FR1± expression in ovarian cancer.. Journal of Clinical Oncology, 2017, 35, e17061-e17061.	0.8	0
111	The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC) and wild-type (no identified targetable mutation) nonsquamous non-small cell lung cancer (WTLC).. Journal of Clinical Oncology, 2017, 35, e18195-e18195.	0.8	0